infliximab vs infliximab-dyyb (Zymfentra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Crohn's Diseasemonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00094458 · Phase 3 · completed

This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).

Next expected readout: November 2026 · NCT05906576 (registry estimate)

Reported efficacy

Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)

Result source: NCT00094458

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03945019 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 396 participants entering induction and 343 entering the randomized maintenance comparison (231 receiving CT-P13 SC and 112 placebo). Both prespecified primary endpoints—CDAI-based clinical remission and endoscopic response at week 54—were met, with each comparison reported as p<0.0001.

Next expected readout: December 2026 · NCT06064864 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinfliximabinfliximab-dyyb (Zymfentra)
Clinical remission (induction)47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
—Not reported
Endoscopic response (induction)—Not posted · NCT00004941—Not reported
Clinical remission (maintenance)66% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
—Not reported
Endoscopic response (maintenance)—Not posted · NCT00004941—Not reported

Clinical remission (induction)

infliximab
47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (induction)

infliximab
—Not posted · NCT00004941
infliximab-dyyb (Zymfentra)
—Not reported

Clinical remission (maintenance)

infliximab
66% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic response (maintenance)

infliximab
—Not posted · NCT00004941
infliximab-dyyb (Zymfentra)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-dyyb (Zymfentra): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. infliximab: 4 of 4 rows · infliximab-dyyb (Zymfentra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinfliximab
Dropout rate
28.4%Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
34.3%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
0%
NCT01580670 · Phase 3 · monotherapy
13.3%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Discontinued due to AEs
16.6%Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
11.8%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—
NCT01580670 · Phase 3 · monotherapy
2.2%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Serious AEs
—Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
—Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14%W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
16%W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
1.9%W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.5%W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14.3%
NCT01580670 · Phase 3 · monotherapy
—
NCT00805766 · Phase 3 · monotherapy
9.1%
NCT00688636 · Phase 4 · registry result, not featured evidence
0%
NCT00791557 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
nausea 21.8%
abdominal pain 13.4%
fatigue 13.4%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 6 more results
abdominal pain 20.9%
nausea 16.6%
arthralgia 14.1%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
abdominal pain 9.3%
nasopharyngitis 8.3%
crohn's disease 5.6%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
abdominal pain 11.3%
nausea 11.3%
vomiting 11.3%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
double stranded dna antibody positive 50%
gastroenteritis 21.4%
headache 21.4%
NCT01580670 · Phase 3 · monotherapy
infusion reaction 18.2% (placebo 7.7%)
abcess 9.1% (placebo 7.7%)
bronchitis 9.1% (placebo 0%)
NCT00688636 · Phase 4 · registry result, not featured evidence
bone marrow suppression 50%
infection 50%
infusion reaction 50%
NCT00791557 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

infliximab

Corticosteroid-free Clinical Remission 44.4% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
56.8% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
60.8% (n=97) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
72.2% (n=108) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Mucosal Healing 30.1% (n=93) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
43.9% (n=107) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Clinical Remission 32.5% (n=169) vs 17.6% (n=170) Azathioprine + Placebo @ 2wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
36.7% (n=169) vs 17.6% (n=170) Azathioprine + Placebo @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
49.1% (n=169) vs 27.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
52.1% (n=169) vs 27.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
47.3% (n=169) vs 34.1% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
59.8% (n=169) vs 34.1% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
49.7% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
60.4% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
47.9% (n=169) vs 31.8% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
60.4% (n=169) vs 31.8% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
66% (n=97) vs 61.3% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
69.4% (n=108) vs 61.3% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
72.2% (n=97) vs 58.7% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
73.1% (n=108) vs 58.7% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
66% (n=97) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
74.1% (n=108) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
CDAI 42.6% (n=169) vs 22.4% (n=170) Azathioprine + Placebo @ 2wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
47.3% (n=169) vs 22.4% (n=170) Azathioprine + Placebo @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
54.4% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
63.3% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
55.6% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
69.2% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
55% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
62.7% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
54.4% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
62.1% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
76.3% (n=97) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
76.9% (n=108) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
74.2% (n=97) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
77.8% (n=108) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
72.2% (n=97) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
78.7% (n=108) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
IBDQ Total 27.7 vs 20.1 Azathioprine + Placebo score @ 2wk
absolute change · score
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 9 more results
31.4 vs 20.1 Azathioprine + Placebo score @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
34.8 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
39.9 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
37.8 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
42.4 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
39.9 vs 30.3 Azathioprine + Placebo score @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
43.7 vs 30.3 Azathioprine + Placebo score @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
39.9 vs 31.4 Azathioprine + Placebo score @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
45.2 vs 31.4 Azathioprine + Placebo score @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Average Corticosteroid Use mg Per 21.2 vs 22.92 Azathioprine + Placebo per day @ 2wk
absolute value · per day
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 9 more results
22.75 vs 22.92 Azathioprine + Placebo per day @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
17.68 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
18.26 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.68 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
15.01 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
13.23 vs 13.49 Azathioprine + Placebo per day @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
11.64 vs 13.49 Azathioprine + Placebo per day @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
10.96 vs 11.57 Azathioprine + Placebo per day @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
9.35 vs 11.57 Azathioprine + Placebo per day @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
PCDAI 78.6% (n=14) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
100% (n=14) @ 6wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 10wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 14wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 18wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 22wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 26wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 30wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 34wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 38wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 42wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 46wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 50wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI 85.7% (n=14) @ 54wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy
PCDAI -20.71 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
-27.68 score @ 6wk
NCT01580670 · Phase 3 · monotherapy
-30 score @ 10wk
NCT01580670 · Phase 3 · monotherapy
-28.57 score @ 14wk
NCT01580670 · Phase 3 · monotherapy
-31.07 score @ 18wk
NCT01580670 · Phase 3 · monotherapy
-27.32 score @ 22wk
NCT01580670 · Phase 3 · monotherapy
-30.18 score @ 26wk
NCT01580670 · Phase 3 · monotherapy
-26.07 score @ 30wk
NCT01580670 · Phase 3 · monotherapy
-30.21 score @ 34wk
NCT01580670 · Phase 3 · monotherapy
-26.25 score @ 38wk
NCT01580670 · Phase 3 · monotherapy
-30.42 score @ 42wk
NCT01580670 · Phase 3 · monotherapy
-27.08 score @ 46wk
NCT01580670 · Phase 3 · monotherapy
-32.5 score @ 50wk
NCT01580670 · Phase 3 · monotherapy
-28.33 score @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI -26.25 score @ 54wk
absolute change · score
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy
PCDAI Remission 42.9% (n=14) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
78.6% (n=14) @ 6wk
NCT01580670 · Phase 3 · monotherapy
71.4% (n=14) @ 10wk
NCT01580670 · Phase 3 · monotherapy
85.7% (n=14) @ 14wk
NCT01580670 · Phase 3 · monotherapy
85.7% (n=14) @ 18wk
NCT01580670 · Phase 3 · monotherapy
71.4% (n=14) @ 22wk
NCT01580670 · Phase 3 · monotherapy
78.6% (n=14) @ 26wk
NCT01580670 · Phase 3 · monotherapy
64.3% (n=14) @ 30wk
NCT01580670 · Phase 3 · monotherapy
83.3% (n=14) @ 34wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 38wk
NCT01580670 · Phase 3 · monotherapy
83.3% (n=14) @ 42wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 46wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 50wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI Remission 64.3% (n=14) @ 54wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy

+ 6 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody (chimeric IgG1)
Weak signal

NCT01585155 · Phase 3 · completed

No randomization, no blinding (masking: NONE), no control arm, single-group design with only 21 patients — this defaults to 'weak' per the design rules regardless of the favorable-looking remission percentages.

Next expected readout: December 2026 · NCT06839820 (registry estimate)

Reported efficacy

Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%

Result source: NCT01585155

infliximab-dyyb (Zymfentra)

Marketed by Celltrion

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT04205643 · Phase 3 · completed

The trial was randomized, quadruple-blind, and placebo-controlled, with 548 participants enrolled and 438 participants included in the reported maintenance analysis. The hard clinical primary endpoint—clinical remission by the modified Mayo score at week 54—was met, with 127 of 294 participants receiving CT-P13 versus 30 of 144 receiving placebo (p<0.0001).

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinfliximabinfliximab-dyyb (Zymfentra)
Clinical remission (induction)—Trial running · NCT06614387—Not reported
Clinical remission (maintenance)—Trial running · NCT06614387—Not reported
Clinical response (induction)—Trial running · NCT06614387—Not reported
Endoscopic improvement (induction)—Trial running · NCT06614387—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT06614387—Not reported

Clinical remission (induction)

infliximab
—Trial running · NCT06614387
infliximab-dyyb (Zymfentra)
—Not reported

Clinical remission (maintenance)

infliximab
—Trial running · NCT06614387
infliximab-dyyb (Zymfentra)
—Not reported

Clinical response (induction)

infliximab
—Trial running · NCT06614387
infliximab-dyyb (Zymfentra)
—Not reported

Endoscopic improvement (induction)

infliximab
—Trial running · NCT06614387
infliximab-dyyb (Zymfentra)
—Not reported

Corticosteroid-free remission (maintenance)

infliximab
—Trial running · NCT06614387
infliximab-dyyb (Zymfentra)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-dyyb (Zymfentra): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. infliximab: 4 of 4 rows · infliximab-dyyb (Zymfentra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinfliximab
Dropout rate
23.8%a
NCT01585155 · Phase 3 · monotherapy
show 3 more results
47.8%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.2%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50%
NCT00791557 · Phase na · registry result, not featured evidence
Discontinued due to AEs
4.8%a
NCT01585155 · Phase 3 · monotherapy
show 3 more results
26.1%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.6%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50%
NCT00791557 · Phase na · registry result, not featured evidence
Serious AEs
14.3%a
NCT01585155 · Phase 3 · monotherapy
show 3 more results
21.7%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.2%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%
NCT00791557 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
double stranded dna antibody positive 57.1%
nasopharyngitis 33.3%
acne 9.5%
NCT01585155 · Phase 3 · monotherapy
show 3 more results
5 mg/kg every 12 weeks
colitis ulcerative 65.2%
upper respiratory tract infection 26.1%
pain 17.4%
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5 mg/kg every 8 weeks
colitis ulcerative 31.8%
upper respiratory tract infection 31.8%
fever 27.3%
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
bone marrow suppression 50%
infection 50%
infusion reaction 50%
NCT00791557 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

infliximab

Clinical Remission 60% (n=21) @ 2wk
responder rate · % of participants
No placebo or comparator arm
Weeks 2
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 80% (n=21) @ 6wk
responder rate · % of participants
No placebo or comparator arm
Weeks 6
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 80% (n=21) @ 8wk
responder rate · % of participants
No placebo or comparator arm
Weeks 8
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 77.8% (n=21) @ 10wk
responder rate · % of participants
No placebo or comparator arm
Weeks 10
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 87.5% (n=21) @ 14wk
responder rate · % of participants
No placebo or comparator arm
Weeks 14
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 87.5% (n=21) @ 18wk
responder rate · % of participants
No placebo or comparator arm
Weeks 18
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 64.3% (n=21) @ 22wk
responder rate · % of participants
No placebo or comparator arm
Weeks 22
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 85.7% (n=21) @ 26wk
responder rate · % of participants
No placebo or comparator arm
Weeks 26
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 64.3% (n=21) @ 30wk
responder rate · % of participants
No placebo or comparator arm
Weeks 30
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 42.9% (n=21) @ 30wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01585155 · Phase 3 · monotherapy
CAI 4 score @ 2wk
absolute change · score
No placebo or comparator arm
Weeks 2
NCT01585155 · Phase 3 · monotherapy
CAI 3.5 score @ 6wk
absolute change · score
No placebo or comparator arm
Weeks 6
NCT01585155 · Phase 3 · monotherapy

+ 31 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: infliximab's landscape · infliximab-dyyb (Zymfentra)'s landscape